Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-Current Debt for 12 consecutive years, with $246.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $246.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $246.4 million, a N/A change, with the full-year FY2025 number at $246.4 million, changed N/A from a year prior.
  • Non-Current Debt was $246.4 million for Q4 2025 at Cytokinetics, up from $158.7 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $246.4 million in Q4 2025 to a low of $30.2 million in Q3 2021.
  • A 5-year average of $81.6 million and a median of $62.5 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: plummeted 34.23% in 2021, then skyrocketed 110.39% in 2022.
  • Cytokinetics' Non-Current Debt stood at $47.4 million in 2021, then surged by 34.71% to $63.8 million in 2022, then decreased by 8.5% to $58.4 million in 2023, then skyrocketed by 59.32% to $93.0 million in 2024, then surged by 164.88% to $246.4 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Non-Current Debt are $246.4 million (Q4 2025), $158.7 million (Q3 2025), and $159.1 million (Q2 2025).